Revenue was up by 2.8% y-o-y to $74.7 million, mainly due to higher sales volume across all product segments and the expanded downstream distribution network.
Gross profit declined by 2.6% y-o-y to $18.3 million, primarily due to higher depreciation expenses of production lines in the third manufacturing facility which has yet to commence operations.
Correspondingly, gross profit margin declined from 25.9% in 1HFY2025 to 24.5% in 1HFY2026.
Other income increased 36.1% y-o-y to S$1.1 million due to the reversal of impairment on property, plant and equipment, which was partially offset by lower interest income.
See also: Reclaims Global reports higher earnings of $6.8 million for FY2026, up 23% y-o-y
Other expenses decreased by 67.4% y-o-y to S$0.6 million in 1HFY2026 due to the reduction in foreign exchange losses.
Net asset value per share increased to 26.53 cents as at Dec 31, 2025, due to higher net cash generated from operations and lower bank borrowings as a result of repayment.
“Excluding non-cash accounting items such as depreciation and amortisation, UG Healthcare’s EBITDA has shown significant improvement compared to the previous year,” says Lee Jun Yih, joint CEO and finance director at UG Healthcare.
See also: The Assembly Place posts 6.4% increase in FY2025 earnings to $6.6 mil
“We remain vigilant and prudent during these uncertain times, continuing to support our customers as they recover and strive to emerge stronger together,” Lee concluded.
Shares in UG Healthcare was unchanged at 9.3 cents on Feb 11.
